Heritage Investors Management Corp Sells 11,118 Shares of Chemours Company (The) (CC)

Heritage Investors Management Corp reduced its position in Chemours Company (The) (NYSE:CC) by 8.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 120,573 shares of the specialty chemicals company’s stock after selling 11,118 shares during the quarter. Heritage Investors Management Corp owned approximately 0.07% of Chemours Company (The) worth $6,102,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in CC. Teachers Advisors LLC increased its position in Chemours Company (The) by 3.3% in the first quarter. Teachers Advisors LLC now owns 319,341 shares of the specialty chemicals company’s stock worth $12,295,000 after buying an additional 10,093 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Chemours Company (The) by 43.8% in the first quarter. Dimensional Fund Advisors LP now owns 706,929 shares of the specialty chemicals company’s stock worth $27,217,000 after buying an additional 215,490 shares during the last quarter. KCG Holdings Inc. purchased a new stake in Chemours Company (The) in the first quarter worth $231,000. United Capital Financial Advisers LLC purchased a new stake in Chemours Company (The) in the first quarter worth $203,000. Finally, Bank of America Corp DE increased its position in Chemours Company (The) by 5.3% in the first quarter. Bank of America Corp DE now owns 631,439 shares of the specialty chemicals company’s stock worth $24,310,000 after buying an additional 31,939 shares during the last quarter. 72.99% of the stock is owned by institutional investors and hedge funds.

In related news, SVP David C. Shelton sold 5,908 shares of the stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $56.01, for a total value of $330,907.08. Following the completion of the transaction, the senior vice president now owns 47,356 shares of the company’s stock, valued at approximately $2,652,409.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider E Bryan Snell sold 10,000 shares of the stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $46.24, for a total transaction of $462,400.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 77,142 shares of company stock valued at $3,953,265. 1.14% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: This report was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://sportsperspectives.com/2017/11/01/heritage-investors-management-corp-sells-11118-shares-of-chemours-company-the-cc.html.

A number of analysts have issued reports on the company. Zacks Investment Research downgraded Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. UBS AG upgraded Chemours Company (The) from a “sell” rating to a “neutral” rating and lifted their price target for the company from $36.00 to $50.00 in a research report on Monday, August 7th. J P Morgan Chase & Co lifted their price target on Chemours Company (The) to $55.00 and gave the company an “overweight” rating in a research report on Friday, August 4th. Argus reiterated a “buy” rating and issued a $55.00 price target (up from $50.00) on shares of Chemours Company (The) in a research report on Thursday, August 10th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $50.00 price target (up from $48.00) on shares of Chemours Company (The) in a research report on Thursday, July 13th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $52.75.

Shares of Chemours Company (CC) traded down 0.19% during midday trading on Wednesday, reaching $56.50. The company’s stock had a trading volume of 246,356 shares. The company has a market cap of $10.44 billion, a PE ratio of 36.98 and a beta of 3.59. Chemours Company has a 12 month low of $15.90 and a 12 month high of $58.08. The company’s 50-day moving average price is $53.72 and its 200-day moving average price is $45.65.

Chemours Company (The) (NYSE:CC) last released its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the prior year, the firm earned $0.27 EPS. The business’s revenue was up 14.8% on a year-over-year basis. On average, equities analysts anticipate that Chemours Company will post $3.57 EPS for the current fiscal year.

Chemours Company (The) Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply